MDM2SNP309 Does Not Associate with Elevated MDM2 Protein Expression or Breast Cancer Risk

Publisher： Karger

E-ISSN： 1423-0232|74|1-2|84-87

ISSN： 0030-2414

Source： Oncology, Vol.74, Iss.1-2, 2008-06, pp. : 84-87

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 1, 2015-07 ,pp. : 96-103

John Wiley & Sons Inc

Access to resources Recommend Favorite

The MDM2 309 T/G Polymorphism is Associated with Head and Neck Cancer Risk Especially in Nasopharyngeal Cancer: A Meta-Analysis

By  

Oncology Research and Treatment, Vol. 35, Iss. 11, 2012-10 ,pp. : 666-670

Karger

Access to resources Recommend Favorite

TP53 mutations and MDM2SNP309 identify subgroups of AML patients with impaired outcome

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 4, 2015-04 ,pp. : 355-362

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Significance of mdm2 and p53 Expression in Bladder Cancer

By  

Oncology, Vol. 56, Iss. 3, 1999-04 ,pp. : 239-247

Karger

Access to resources Recommend Favorite

Targeted nutlin-3a loaded nanoparticles inhibiting p53––MDM2 interaction: novel strategy for breast cancer therapy

By Das Manasi   Dilnawaz Fahima   Sahoo Sanjeeb K  

Nanomedicine, Vol. 6, Iss. 3, 2011-04 ,pp. : 489-507

Future Medicine

Access to resources Recommend Favorite